Solid Tumor Malignancies
41
21
22
5
Key Insights
Highlights
Success Rate
56% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.8%
4 terminated out of 41 trials
55.6%
-31.0% vs benchmark
7%
3 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (41)
Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study
ECMO Use in Pediatric Oncology and HSCT Patients: A Descriptive and Comparative Analysis
Clinical Evaluation of [68Ga]Ga-FFD PET Imaging in Healthy Volunteers and Patients With Solid Tumors
GKL-006Allo Injection in Patients With Advanced Solid Tumors
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
xDRIVE for Florida-based Cancer Patients
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression